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Abstract. 
 
By incubating at 30
 
8
 
C in the presence of an 
energy source, p34
 
cdc2
 
/cyclin B was activated in the ex-
tract prepared from a temperature-sensitive mutant, 
tsBN2, which prematurely enters mitosis at 40
 
8
 
C, the 
nonpermissive temperature (Nishimoto, T., E. Eilen, 
 
and C. Basilico. 1978. 
 
Cell
 
. 15:475–483), and wild-type 
cells of the hamster BHK21 cell line arrested in S 
phase, without protein synthesis. Such an in vitro acti-
vation of p34
 
cdc2
 
/cyclin B, however, did not occur in the 
extract prepared from cells pretreated with protein syn-
thesis inhibitor cycloheximide, although this extract still 
retained the ability to inhibit p34
 
cdc2
 
/cyclin B activation. 
When tsBN2 cells arrested in S phase were incubated at 
40
 
8
 
C in the presence of cycloheximide, Cdc25B, but not 
Cdc25A and C, among a family of dual-specificity phos-
phatases, Cdc25, was lost coincidentally with the lack of 
the activation of p34
 
cdc2
 
/cyclin B. Consistently, the im-
munodepletion of Cdc25B from the extract inhibited 
the activation of p34
 
cdc2
 
/cyclin B. Cdc25B was found to 
be unstable (half-life 
 
,
 
 30 min). Cdc25B, but not 
Cdc25C, immunoprecipitated from the extract directly 
activated the p34
 
cdc2
 
/cyclin B of cycloheximide-treated 
cells as well as that of nontreated cells, although 
Cdc25C immunoprecipitated from the extract of mi-
totic cells activated the p34
 
cdc2
 
/cyclin B within the ex-
tract of cycloheximide-treated cells. Our data suggest 
that Cdc25B made an initial activation of p34
 
cdc2
 
/cyclin 
B, which initiates mitosis through the activation of 
Cdc25C.
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1. 
 
Abbreviations used in this paper
 
: CAK, CDK-activating kinase; CDK,
cyclin-dependent kinase; HU, hydroxyurea; PCC, premature chromatin
condensation; ts, temperature sensitive.
 
T
 
he
 
 activation of the cdks is a central issue of cell cy-
cle regulation. From S phase, cyclin B accumulates
and binds to p34
 
cdc2
 
. Upon binding to cyclin B,
p34
 
cdc2
 
 is phosphorylated on Thr-161, a site essential for
the catalytic activity of p34
 
cdc2
 
. Simultaneously, p34
 
cdc2
 
 is
phosphorylated on Thr-14 and Tyr-15 to prevent the pre-
mature activation of p34
 
cdc2
 
/cyclin B (for review see by
Dunphy, 1994). The phosphorylation of Thr-161 is carried
out by cyclin-dependent kinase (CDK)
 
1
 
-activating kinase
(CAK; Shuttleworth et al., 1990; Solomon et al., 1992,
1993; Fesquet et al., 1993; Poon et al., 1993), and the phos-
phorylation at Thr-14 and Tyr-15 is performed by both
Wee1/Mik1 (Featherstone and Russell, 1991; Parker and
Piwnica-Worms, 1992; Lee et al., 1994
 
b
 
; Mueller et al.,
1995
 
a
 
) and Myt1 kinases (Mueller et al., 1995
 
b
 
). 
 
Xenopus
 
Cdc25, a dual-specificity phosphatase, dephosphorylates
both Thr-14 and Tyr-15 (Izumi et al., 1992; Kumagai and
Dunphy, 1992). During S phase, the activity of Thr-14 and
Tyr-15 kinase is held high, and the activity of Cdc25 is low.
When DNA replication is completed, the balance between
Thr-14 and Tyr-15 kinase and Cdc25 phosphatase is
switched to activate p34
 
cdc2
 
/cyclin B. In mammalian cells,
Cdc25 is comprised of Cdc25A, Cdc25B, and Cdc25C
(Sadhu et al., 1990; Galaktionov and Beach, 1991; Nagata
et al., 1991; Millar et al., 1991). All three Cdc25 species are
functional homologues of the 
 
Schizosaccharomyces pombe
cdc25
 
1
 
 gene. Cdc25A is expressed in late G
 
1
 
 and has been
reported to be required for initiation of S phase (Jinno et
al., 1994), whereas the role of Cdc25B in the cell cycle re-
mains vague. It is thought to be required for mitosis
(Galaktionov and Beach, 1991; Nagata et al., 1991; Honda
et al., 1993) and for development of human cancer (Galak-
tionov et al., 1995). On the other hand, Cdc25C, which is
phosphorylated and thereby activated by p34
 
cdc2
 
/cyclin B,
induces the full activation of p34
 
cdc2
 
 by forming a positive
feedback mutual activation loop (Kumagai and Dunphy,
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1992; Hoffmann et al., 1993; Izumi and Maller, 1993). A
trigger for a full activation of p34
 
cdc2
 
/cyclin B that initiates
mitosis is unknown. It is supposed to be carried out by the
balance between cyclin and PP2A (Solomon et al., 1990;
Lee et al., 1991, 1994
 
a
 
). PP2A inhibits Thr-161 phosphory-
lation (Lee et al., 1994
 
a
 
), and the increment of cyclin accu-
mulates the p34
 
cdc2
 
/cyclin B complexes, which titrates out
the stoichiometric inhibitors of the p34
 
cdc2
 
/cyclin B com-
plex (Kumagai and Dunphy, 1995; Lee and Kirschner,
1996). Recently, Cdc25C has been found to be phosphory-
lated and thereby activated by Plx1 POLO-like kinase
(Kumagai and Dunphy, 1996). Wee1 tyrosine kinase is in-
activated by Nim1 serine/threonine kinase in 
 
S. pombe
 
(Wu and Russell, 1993). Nim1p is localized within the cy-
toplasm and Wee1p within the nucleus (Wu et al., 1996).
Similarly, in BHK21 cells, Cdc25C is localized within the
cytoplasm and Wee1p within the nucleus (Heald et al.,
1993). In HeLa cells, cyclin B has been reported to be lo-
calized within the cytoplasm (Pines and Hunter, 1991,
1994). To initiate mitosis, therefore, Nim1p, Cdc25C, and
cyclin B are supposed to enter the nucleus. Thus, in addi-
tion to protein phosphorylation, the cellular compartment
is thought to play a role in the cell cycle regulation.
In hamster BHK21 cells arrested in S phase, p34
 
cdc2
 
/cy-
clin B is prematurely activated, and cells enter mitosis ei-
ther by temperature-sensitive (ts) BN2 mutation of BHK21
cell line or by the administration of caffeine, resulting in
premature chromatin condensation (PCC; Nishimoto et
al., 1978; Schlegel and Pardee, 1986). In both cases, pro-
tein synthesis inhibitors block PCC induction (Nishimoto
et al., 1981; Schlegel and Pardee, 1986; Nishitani et al.,
1991). These findings have been considered to indicate
that a new synthesis of proteins is required for the activa-
tion of p34
 
cdc2
 
/cyclin B. Wasserman and Masui (1975) orig-
inally found that protein synthesis inhibitors block the
 
Xenopus
 
 oocyte maturation induced by progesterone. As
a protein that is newly synthesized by progesterone treat-
ment, cyclin B was plausible, since it is synthesized from S
phase onwards and is essential for p34
 
cdc2
 
/cyclin B activa-
tion (Evans et al., 1983). However, cyclin B already exists
in 
 
Xenopus
 
 oocytes (Minshull et al., 1991) and also in
BHK21 cells arrested in S phase (Nishitani et al., 1991).
Another candidate for a newly synthesized activator is a
c-mos proto-oncogene product (MOS)-like protein. In
 
Xenopus
 
 oocyte, MOS that is synthesized just before mei-
osis I is essential for the activation of p34
 
cdc2
 
/cyclin B (Sa-
gata et al., 1988). Microinjected MOS protein can induce
meiosis I, but not meiosis II, without protein synthesis
(Yew et al., 1992; Furuno et al., 1994). Thus, the synthesis
of protein(s) other than MOS appears to be required to
complete 
 
Xenopus
 
 oocyte maturation. Alternatively, if
 
Xenopus
 
 oocytes and BHK21 cells arrested in S phase
contain all the molecules required for p34
 
cdc2
 
/cyclin B acti-
vation, the inhibition of p34
 
cdc2
 
/cyclin B activation caused
by blocking protein synthesis may reflect the loss of en-
dogenous activators of p34
 
cdc2
 
/cyclin B that are rapidly
turning over.
tsBN2 mutation causes the loss of RCC1 function, re-
sulting in either G
 
1
 
 arrest or premature activation of
p34
 
cdc2
 
/cyclin B depending on the cell cycle stage (Nishi-
moto et al., 1978; Nishitani et al., 1991). RCC1 is localized
on chromatin (Frasch, 1991) and functions as a GDP/GTP
 
exchanging factor on Ran, a Ras-like nuclear G protein
(Bischoff and Ponstingle, 1991). GTP hydrolysis of Ran is
essential for the nuclear import of karyophilic proteins
(Melchior et al., 1993; Moore and Blobel, 1993). It can be
argued, therefore, that all of the phenotypes of 
 
rcc1
 
2
 
 are
indirect consequences of the role of Ran in nuclear trans-
port. However, PCC induced by the loss of RCC1 can be
inhibited by microinjection of both GTP- and GTP
 
g
 
S-
bound Ran (Ohba et al., 1996), indicating that GTP-Ran
plays some role in the nucleus. This finding is consistent
with the fact that Yrb2p that possesses a Ran-binding do-
main similar to RanBP1/Yrb1p (Dingwall et al., 1995),
thereby specifically binding to the GTP-bound Gsp1p 
 
S.
cerevisiae
 
 Ran homologue, is localized in the nucleus
(Noguchi et al., 1997). The disruptant of the 
 
YRB2
 
 gene,
which is cold sensitive, has no defect in the nucleus/cytosol
exchange of macromolecules (Noguchi et al., 1997).
When tsBN2 cells are incubated in S phase at 40
 
8
 
C, the
nonpermissive temperature, Cdc25C enters the nucleus
parallel with PCC induction (Seki et al., 1992). This is in-
consistent with the findings that the loss of RCC1 function
retards nuclear protein import (Tachibana et al., 1994;
Dickmanns et al., 1996). We noticed the fact that the inhi-
bition of protein synthesis blocks the nuclear import of
Cdc25C as well as the activation of p34
 
cdc2
 
/cyclin B (Seki et
al., 1992), which suggests that loss of RCC1 function in-
duces a new protein synthesis required either for nuclear
entrance of Cdc25C or for the activation of p34
 
cdc2
 
/cyclin
B. To clarify the relationship between the loss of RCC1
and the p34
 
cdc2
 
/cyclin B activation, we began to identify
the protein(s) required for p34
 
cdc2
 
/cyclin B activation in-
duced by loss of RCC1 (Nishitani et al., 1991). To do this,
we have first established a method to activate the p34
 
cdc2
 
/
cyclin B complexes in vitro by using the extract prepared
from BHK21 cells arrested in S phase (Seki et al., 1992). In
this paper, we confirmed our previous results by using
tsBN2 cells. We found that the in vitro activation of
p34
 
cdc2
 
/cyclin B occurred without new protein synthesis
and that p34
 
cdc2
 
/cyclin B was not activated in the extract of
cells pretreated with protein synthesis inhibitor. Instead of
a new synthesis of p34
 
cdc2
 
/cyclin B activators, therefore, an
endogenous activator(s) of p34
 
cdc2
 
/cyclin B was suggested
to be lost by blocking protein synthesis. Cdc25B, but not
Cdc25C or Cdc25A, was identified as such an unstable ac-
tivator of p34
 
cdc2
 
/cyclin B.
 
Materials and Methods
 
Cells and Cell Culture
 
The BHK21 cell line derived from golden hamsters and its ts mutant
tsBN2 cell line (Nishimoto et al., 1978) and human HeLa cell line were
grown in DME containing 10% calf or FCS in a humidified atmosphere
containing 10% CO
 
2
 
. HeLa cells were cultured at 37.5
 
8
 
C, and BHK21 and
tsBN2 cells were cultured at 33.5
 
8
 
C. As the nonpermissive temperature,
40
 
8
 
C was used for tsBN2 cells.
 
Synchronization of Cells
 
Wild-type BHK21 and tsBN2 cells were cultured in isoleucine-free me-
dium for 24–30 h (G
 
0
 
/G
 
1
 
 arrest) and then in DME containing 10% FCS
and 2.5 mM hydroxyurea (HU) for 15.5 h (S phase arrest) as described
(Nishitani et al., 1991). To synchronize in mitosis, after the release from
HU block, cells were incubated in DME medium containing 10% FCS
and 0.4 
 
m
 
g/ml Nocodazole for 8 h. 
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HeLa cells were cultured in medium containing thymidine (2 mM) for
14 h, in a normal growth medium for 13 h, and finally in medium contain-
ing 2.5 mM HU for 14 h (S phase arrest).
 
Preparation of Cell Extracts
 
Cells were collected with a scraper and then sequentially washed, first
with TD buffer containing 136.8 mM NaCl, 5 mM KCl, 0.7 mM Na
 
2
 
HPO
 
4
 
,
and 25 mM Tris-HCl (pH 7.4), with the EB buffer, and finally with the 0.5
 
3
 
 EB buffer as described (Seki et al., 1992). The EB buffer contained 20
mM Hepes-KOH (pH 7.4), 50 mM KCl, 50 mM 2-glycerophosphate, 15
mM EGTA, and 10 mM MgCl
 
2
 
. Washed cells were lysed by pipetting and
vortexing in the buffer (0.5 
 
3
 
 EB-1), 0.5 
 
3
 
 EB buffer supplemented with
5 
 
m
 
g/ml cytochalasin B, 5 mM DTT, a mixture of protease inhibitors, 1
mM ATP-
 
g
 
-S, and 0.5% NP-40. After being kept on ice for 30 min, the ex-
tract was centrifuged at 2,000 
 
g
 
 for 5 min. The supernatant was further
centrifuged at 80,000 
 
g
 
 for 30 min. The resulting supernatant was used as
the cytosolic extracts. The total cell extract was prepared with the same
procedure, except that the cells were lysed directly in the 0.5 
 
3
 
 EB-1
buffer supplemented with 500 mM NaCl. The mixture of protease inhibi-
tors contained 2 
 
m
 
g/ml of aprotinin, antipain dihydrochloride, leupeptin,
and pepstatin A, and 100 
 
m
 
M 
 
p
 
-amidinophenyl methansulfonyl fluoride
(
 
p
 
APMSF).
The cell extracts were desalted, concentrated by centricon (Amicon
Corp., Danvers, MA), and then subjected to use as the cell extracts for the
in vitro activation assay of p34
 
cdc2
 
 protein kinase.
 
Preparation of E. coli-Produced Hamster Cdc25C
 
E. coli
 
 BL21 (DE3)LysS/pGEX-KG-hamster Cdc25C (a gift of K. Ya-
mashita, Kyushu University, Fukuoka, Japan) strains were cultured at
30
 
8
 
C up to an OD 600 of 0.4, treated with IPTG (final concentration, 1.0
mM) for 3 h, and then collected by centrifugation. Cell-pellet was lysed
and glutathione-S-transferase (GST)-Cdc25C was purified using glu-
tathione Sepharose 4B beads (Pharmacia Fine Chemicals, Piscataway, NJ)
as described previously (Noguchi et al., 1997). Eluted GST-Cdc25C was
further purified by gel filtration using Sephacryl S-100 HR column (Phar-
macia Fine Chemicals).
 
Immunodepletion of cyclin B, cdc25B, and cdc25C from 
Cytoplasmic Extract
 
The antibody was mixed with protein G Sepharose (Pharmacia Fine
Chemicals), rotated at 4
 
8
 
C for 2 h. Beads were pulled down by centrifuga-
tion, washed with 0.5 
 
3
 
 EB-1 buffer, and then suspended in the cytosolic
extracts. After rotation for 2 h at 4
 
8
 
C, the beads were pulled down by cen-
trifugation. The resulting supernatant was used as immunodepleted ex-
tracts.
 
In Vitro Activation of p34
 
cdc2
 
 Histone H1 Kinase and 
Assay of Histone H1 Kinase Activity
 
The extract of 5–15 
 
m
 
l (protein concentration: 3 mg/ml) was incubated at
30
 
8
 
C in the presence of 1 mM ATP, 10 mM creatine phosphate, and 2.5
 
m
 
g/ml creatine kinase as an energy source (Kumagai and Dunphy, 1992).
The reaction was stopped by a buffer containing 40 mM Hepes-NaOH
(pH 7.5), 60 mM 2-glycerophosphate, 20 mM 
 
p
 
-nitrophenyl phosphate, 0.5
mM Na
 
3
 
VO
 
4
 
, 250 mM NaCl, 15 mM MgCl
 
2
 
, 1% Triton X-100, 1 mM DTT,
and a mixture of protease inhibitors. p34
 
cdc2
 
/cyclin B complexes were pre-
cipitated with the anti-cyclin B1 antibody or the p13
 
suc1
 
 beads (Nishitani et
al., 1991), as indicated. The histone H1 kinase activity of precipitates was
assayed by using the histone H1 as the substrate, as described (Nishitani et
al., 1991).
The reaction was carried out more than twice by using different extracts.
 
Immunoblotting
 
Antibodies used were the anti-cdc2 antibodies against PSTAIR peptide
(Nishitani et al., 1991), the anti-phosphotyrosine antibody, pTyr (a gift of
Dr. J.Y.J. Wang, University of California, San Diego, CA; Morla and
Wang, 1986), and the antibodies against cdc25A, cdc25B and cdc25C anti-
bodies (Seki et al., 1992), cyclin B, and cdk2 (all from Santa Cruz Biotech-
nology, Santa Cruz, CA). The procedure for immunoblotting was carried
out as described elsewhere (Nishitani et al., 1990), except that the detec-
tion was achieved using an ECL detection system (Amersham).
 
Pulse–Chase of Cdc25B
 
Cells were preincubated in methionine-free medium for 1 h and then la-
beled with 100 
 
m
 
Ci/ml of [
 
35
 
S]
 
l
 
-methionine (ICN Biochemicals Inc., Ir-
vine, CA) for 3 h. After washing out the labeled medium, cells were given
the medium containing ten times the concentration (2 mM) of methionine.
Cdc25B was immunoprecipitated using the anti-Cdc25B antibody, electro-
phoresed in SDS–10% polyacrylamide gel, and analyzed by autoradiography.
 
Transient Over-Expression of Cdc25B
 
Wild-type BHK21 cells were seeded, and after 18 to 23 h of incubation at
33.5
 
8
 
C, cells were transfected with plasmid pcD2-human Cdc25B (a gift
from H. Okayama, Tokyo University, Tokyo, Japan) using lipofection (Li-
pofectamin
 
TM
 
; GIBCO BRL, Gaithersburg, MD) as described previously
(Makishima et al., 1997).
 
Results
 
In Vitro Activation of p34
 
cdc2
 
/cyclin B
 
A series of cultures of tsBN2 cells arrested in S phase
(throughout this paper, cells were arrested in S phase ex-
cept for the case mentioned) was incubated at 40
 
8
 
C, the
nonpermissive temperature. Every hour, cells were har-
vested and lysed. From the total cell extracts prepared,
p34
 
cdc2
 
/cyclin B complexes were precipitated with p13
 
suc1
 
beads and assayed for histone H1 kinase activity as de-
scribed in Materials and Methods. As previously reported
(Nishitani et al., 1991), the histone H1 kinase activity of
p34
 
cdc2
 
/cyclin B increased by incubating tsBN2 cells at
408C (Fig. 1 A). When the same extracts were incubated in
vitro at 308C, the histone H1 kinase activity of p34cdc2/cy-
clin B was also increased (Fig. 1 B). Such an in vitro activa-
tion of p34cdc2/cyclin B occurred in the extract of tsBN2 cells
prepared before increasing the temperature (Fig. 1 A, 0 h),
as well as in the extract of tsBN2 cells that had been incu-
bated at 408C for 1 h and had no histone H1 kinase activity
yet (Fig. 1 A, 1 h). The finding that p34cdc2/cyclin B was ac-
tivated in the cell extracts prepared from tsBN2 cells that
had been harvested before increasing the temperature in-
dicated that the disruption of cells, rather than the muta-
tion of tsBN2 cells, induced an in vitro activation of
p34cdc2/cyclin B. To address this issue, the extract was pre-
pared from wild-type BHK21 cells and incubated at 308C
for 1 h. To specifically detect the activity of p34cdc2/cyclin B
complex, we used, henceforth, the anti-cyclin B antibody
instead of p13suc1 beads. The p34cdc2/cyclin B was activated
in the extract of wild-type BHK21 cells (Fig. 2, columns 3
and 4) as reported (Seki et al., 1992).
In parallel with the activation of p34cdc2/cyclin B, the mo-
lecular mass of p34cdc2 was reduced, as reported (Ather-
ton-Fessler et al., 1994), consistent with the dephosphory-
lation of Tyr-15 of p34cdc2, which was confirmed by using
the anti-pTyr antibody that specifically recognizes phos-
phorylated tyrosine (Morla and Wang, 1986) (Fig. 3).
Protein Synthesis Required for Activation of
p34cdc2/cyclin B
In the presence of protein synthesis inhibitor, while RCC1
disappears due to the mutation, the activation of p34cdc2/
cyclin B does not occur in tsBN2 cells arrested in S phase,
at 408C, the nonpermissive temperature (Nishimoto et al.,
1981; Nishitani et al., 1991). To investigate the effect ofThe Journal of Cell Biology, Volume 138, 1997 1108
protein synthesis inhibitor on the activation of p34cdc2/cy-
clin B, we prepared the extracts from S phase-arrested
wild-type BHK21 cells that had been incubated in the
presence of protein synthesis inhibitor cycloheximide (10
mg/ml) for 1 h before cell harvest (henceforth designated
cycloheximide treated). When the extract of cyclohexi-
mide-treated cells was incubated at 308C for 1 h, there was
no activation of p34cdc2/cyclin B (Fig. 2, columns 1 and 2),
consistent with the finding that p34cdc2 was not dephosphor-
ylated (Fig. 3, lanes 1 and 2). Therefore, cycloheximide-
treated cells had no ability to activate the p34cdc2/cyclin B
complexes, both in vivo and in vitro.
To exclude the possibility that cycloheximide carried
over from cycloheximide-treated cells inhibited the activa-
tion of p34cdc2/cyclin B, the extract was prepared from
wild-type BHK21 cells that had not been treated with cy-
cloheximide, and then incubated in vitro either in the pres-
ence or absence of 10 mg/ml of cycloheximide. In both
cases, p34cdc2/cyclin B was activated (Fig. 2, compare col-
umns 4 and 6), indicating that BHK21 cells that were ar-
rested in S phase possessed all molecules required for the
observed in vitro activation of p34cdc2/cyclin B. The lack of
activation of p34cdc2/cyclin B in the extract prepared from
Figure 1. In vivo and in vitro
activation of p34cdc2/cyclin B
in tsBN2 cells. (A) Cultures
of tsBN2 cells synchronized
in S phase with HU were in-
cubated at 408C in the pres-
ence of HU. Every hour, cells
were harvested and lysed to
prepare the total cell extract.
From 10 ml (protein concen-
tration: 3 mg/ml) of the total
cell extract, the p34cdc2/cyclin
B complexes were precipitated
using p13suc1 beads and as-
sayed for histone H1 kinase
activities. (B) The total cell
extracts prepared from tsBN2
cells that had been incu-
bated at 408C for 0 (–h–), 1
(–r–), 2 (–j–), and 3 (–e–) h
were incubated at 308C. Every hour, 10 ml of the extracts (protein concentration: 3 mg/ml) were sampled and mixed with the reaction-
stopping buffer. The p34cdc2/cyclin B complexes were precipitated using p13suc1 beads and assayed for histone H1 kinase activities. His-
tone H1 kinase activities shown in A correspond to the value at the beginning of incubation (time: 0) in B as shown by arrows.
Figure 2. In vitro activation of p34cdc2/cyclin B in wild-type
BHK21 cells. Cultures of wild-type BHK21 cells synchronized in
S phase with HU were incubated in the presence (CHX-treated,
columns 1 and 2) or absence (non-treated, columns 3–6) of cyclo-
heximide (10 mg/ml) for 1 h and then lysed to prepare the cyto-
solic extracts, as described in Materials and Methods. The cytosolic
extracts were incubated at 308C in the absence (columns 1 to 4)
or presence (columns 5 and 6) of cycloheximide (10 mg/ml). Be-
fore incubation (columns 1, 3, and 5) or after incubation for 1 h
(columns 2, 4, and 6), 8 ml of the extracts (protein concentration:
3 mg/ml) were mixed with the reaction-stopping buffer. p34cdc2/
cyclin B complexes were immunoprecipitated using the anti-
cyclin B antibodies and assayed for histone H1 kinase activities.
Figure 3. Dephosphorylation of p34cdc2 occurs in parallel with the
activation of p34cdc2/cyclin B. Wild-type BHK21 cells synchro-
nized in S phase with HU were incubated in the presence (lanes 1
and 2) or absence (lanes 3 and 4) of cycloheximide (10 mg/ml) for
1 h and then lysed to prepare the total cell extracts. The total cell
extracts were incubated at 308C. Before incubation (lanes 1 and
3), and after incubation for 1 h (lanes 2 and 4), the extracts were
mixed with SDS-sample buffer and boiled. Total proteins of the
mixtures were electrophoresed in SDS-10% polyacrylamide gel
and analyzed by immunoblotting using as a probe, anti-pTyr
(top) and the anti-PSTAIR (bottom), respectively.Nishijima et al. Cdc25B, Starter of p34cdc2/Cyclin B Activation 1109
cycloheximide-treated cells, therefore, suggested that some
molecules or protein modifications required for the activa-
tion of p34cdc2/cyclin B were lost during the blocking of
protein synthesis.
Activator(s), but Not Inhibitor(s) of p34cdc2/cyclin B 
Was Lost by Blocking Protein Synthesis
To investigate the possibility that the activator(s) of
p34cdc2/cyclin B was lost by blocking protein synthesis, the
extract was prepared from S phase-arrested BHK21 cells
that had been either treated with cycloheximide or not
treated with cycloheximide (henceforce designated non-
treated) as described in Materials and Methods. To ex-
clude the possibility that p34cdc2/cyclin B is involved in the
activation step, the p34cdc2/cyclin B complexes were depleted
using the anti-cyclin B antibodies, from these extracts. The
cyclin B-depleted extracts were then mixed and incubated
at 308C, with the extract prepared either from cyclohexi-
mide-treated or from nontreated cells, respectively.
The cyclin B-depleted extract prepared from nontreated
cells, while it had no activity of p34cdc2/cyclin B (Fig. 4 C),
possessed the ability to activate the p34cdc2/cyclin B within
the extract prepared from cycloheximide-treated cells
(Fig. 4 A). On the other hand, the cyclin B-depleted ex-
tract prepared from cycloheximide-treated cells had no
ability to activate the p34cdc2/cyclin B within the extract
prepared from cycloheximide-treated cells. To the con-
trary, the cyclin B-depleted extract of cycloheximide-
treated cells was found to have the ability to inhibit the in
vitro activation of p34cdc2/cyclin B (Fig. 4 B). These find-
ings indicated that wild-type BHK21 cells that were ar-
rested in S phase possessed both the activator(s) and the
inhibitor(s) of p34cdc2/cyclin B. By blocking protein syn-
thesis, the activator(s), which was not the endogenous
p34cdc2/cyclin B complex, was lost, but the inhibitor(s) re-
mained. The inhibitory activity for p34cdc2/cyclin B of the
cycloheximide-treated cell extracts may reflect either the
activation of p34cdc2/cyclin B inhibitor(s) or the loss of bal-
ance between the inhibitor and the activator of p34cdc2/cy-
clin B.
Cdc25B Was Lost by Blocking Protein Synthesis
To identify proteins that were required for p34cdc2/cyclin B
activation and disappeared during treatment of cells with
protein synthesis inhibitors, cultures of tsBN2 cells were
synchronized in S phase at 33.58C and then incubated at
408C, either in the absence or presence of cycloheximide
(10 mg/ml). Every hour, cells were harvested and assayed
for the presence of p34cdc2/cyclin B activators, such as
Cdc25A, B, and C, and as controls, p34cdk2, p34cdc2, and cy-
clin B, by immunoblotting analysis (Fig. 5).
While p34cdc2/cyclin B was activated in tsBN2 cells with-
out cycloheximide, no activation of p34cdc2/cyclin B oc-
curred in the presence of cycloheximide as previously re-
ported (Nishitani et al., 1991; Fig. 5 A). Parallel with the
activation of p34cdc2/cyclin B, the molecular mass of p34cdc2
was shifted down to the faster-migration form, while that
of Cdc25C was shifted up to the retarded-migration form
(Fig. 5 B), as previously reported (Izumi et al., 1992; Kuma-
gai and Dunphy, 1992; Seki et al., 1992; Hoffmann et al.,
1993). In tsBN2 cells treated with cycloheximide, the mo-
lecular mass of both Cdc25C and p34cdc2 did not change,
consistent with the fact that there was no activation of
p34cdc2/cyclin B. The amount of Cdc25A and C and p34cdc2
seemed to be constant during treatment with cyclohexi-
mide. However, Cdc25B became undetectable after inhib-
iting protein synthesis for 1 h. Loss of Cdc25B was also ob-
served in cycloheximide-treated wild-type BHK21 cells
(Fig. 6 A), indicating that Cdc25B was an unstable protein
in BHK21 cells.
Interestingly, even in the absence of cycloheximide, the
amount of Cdc25B was gradually reduced and finally lost
in parallel with the reduction in histone H1 kinase activity
of p34cdc2/cyclin B, similar to cyclin B (Fig. 5, compare A
and B).
Cdc25B Is an In Vitro Activator of p34cdc2/cyclin B
To confirm that Cdc25B is an activator required for the in
vitro activation of p34cdc2/cyclin B, Cdc25B, and as a con-
trol, Cdc25C, which is essential for p34cdc2/cyclin B activa-
Figure 4. Both activator(s) and inhibitor(s) of p34cdc2/cyclin B are present in HU-arrested BHK21 cells. Cultures of wild-type BHK21
cells synchronized in S phase with HU were incubated in the absence (nontreated) or presence (CHX-treated) of cycloheximide (10 mg/
ml) for 1 h and then lysed to prepare the cytosolic extracts. When indicated as cyclin B-depleted, the p34cdc2/cyclin B complexes were im-
munoprecipitated using the anti-cyclin B antibody and the supernatant was used as the cyclin B-depleted extracts as described in Mate-
rials and Methods. 8 ml of the total cytosolic extracts prepared from CHX-treated cells (A), from nontreated cells (B), and as a control
of the buffer (0.53 EB-1; C) were mixed with 0, 4, 8, 16, and 32 ml of the cyclin B-depleted extracts prepared from nontreated (–d–) or
CHX-treated cells (–s–). In each case, the final volume was adjusted to 40 ml with the buffer (0.5 3 EB-1). After incubation at 308C for
1 h, the p34cdc2/cyclin B complexes were immunoprecipitated using the anti-cyclin B antibodies and assayed for histone H1 kinase activ-
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tion induced by loss of RCC1 (Seki et al., 1992), were de-
pleted from the cytosolic extract prepared from nontreated,
wild-type BHK21 cells, using the anti-Cdc25B and Cdc25C
antibodies, respectively. Depletion of Cdc25B and Cdc25C
was confirmed by immunoblotting analysis (Fig. 6 A). In
both cases, Cdc25A remained in the extracts.
Cdc25B- and Cdc25C-depleted extracts were then incu-
bated at 308C for 1 h. The p34cdc2/cyclin B complex was ac-
tivated in the Cdc25C-depleted extract, but not in the
Cdc25B-depleted extract (Fig. 6 B, cdc25B and cdc25C).
The effect of Cdc25B depletion was further confirmed us-
ing the extracts from which p34cdc2/cyclin B had been de-
pleted, in addition to Cdc25B or CdC25C. These extracts
alone possessed no activity of p34cdc2/cyclin B. However,
as shown in Fig. 6 C, the cyclin B- and Cdc25C-depleted
extract contained the ability to activate the p34cdc2/cyclin B
complex of the extract prepared from cycloheximide-
treated cells, whereas the cyclin B- and Cdc25B-depleted
extract did not.
To further confirm the involvement of Cdc25B in the in
vitro activation of p34cdc2/cyclin B, proteins were immuno-
precipitated from the extracts of cycloheximide-treated
and nontreated cells, using the anti-Cdc25B antibody and
assayed for their abilities to activate the p34cdc2/cyclin B
complex within the extract of cycloheximide-treated cells.
Proteins that were immunoprecipitated from the extracts
of nontreated cells activated p34cdc2/cyclin B, but those
precipitated from cycloheximide-treated cells did not (Fig.
7 A). In both cases, immunoprecipitated proteins alone
had no activity of histone H1 kinase. As a control, Cdc25C
was immunoprecipitated from the extract of BHK21 cells
arrested either in S phase or in mitosis. While Cdc25C de-
rived from mitotic cells had an ability to activate the
p34cdc2/cyclin B complex within the extract of cyclohexi-
mide-treated cells, Cdc25C derived from S phase-arrested
cells did not (Fig. 7 B). These findings indicated that
Cdc25B was an activator of the p34cdc2/cyclin B complex,
which was lost by cycloheximide treatment.
Cdc25B Directly Activated p34cdc2/cyclin B
To address the question of whether Cdc25B directly acti-
vate p34cdc2/cyclin B, Cdc25B was immunoprecipitated
from the extract of nontreated cells, and as a control, from
the extract of cycloheximide-treated cells. On the other
hand, the p34cdc2/cyclin B complexes were immunoprecipi-
tated using the anti-cyclin B antibody, from the extracts of
cycloheximide-treated and nontreated cells. Proteins im-
munoprecipitated with the anti-Cdc25B antibody alone
had no activity of histone H1 kinase (Fig. 8, base line). By
mixing with the p34cdc2/cyclin B, which had no histone H1
kinase activity by itself (Fig. 8, zero point), Cdc25B of non-
treated cells activated p34cdc2/cyclin B complexes isolated
from both the extracts of nontreated and cycloheximide-
treated cells, with a similar kinetics (Fig. 8, A and B). As a
control, mock-precipitated Cdc25B from cycloheximide-
treated cells had no ability to activate p34cdc2/cyclin B.
Compared to the p34cdc2/cyclin B retained within the ex-
tract, the isolated p34cdc2/cyclin B complexes were highly
activated by Cdc25B (compare Fig. 7 and 8). This finding
may suggest that the inhibitors for p34cdc2/cyclin B activa-
tion retained within the extracts were removed from the
p34cdc2/cyclin B complexes by immunoprecipitation. With
these results taken together, we concluded that Cdc25B di-
rectly activated the p34cdc2/cyclin B complex, while we
could not exclude the possibility that some proteins that
were co-precipitated with p34cdc2/cyclin B or with Cdc25B,
activated Cdc25B before the activation of p34cdc2/cyclin B
(Galaktionov and Beach, 1991). These findings also indi-
cated that the protein modification required for the activa-
tion of p34cdc2/cyclin B was not lost by blocking protein
synthesis.
Cdc25B Is a Short-Life Protein in Mammalian Cells
Our present results suggest that Cdc25B was lost in tsBN2
and wild-type BHK21 cells treated with protein synthesis
Figure 5. Cdc25B was lost by treatment with cycloheximide. A
series of cultures of tsBN2 cells synchronized in S phase with HU
was incubated at 408C in the absence (nontreated) or presence
(CHX-treated) of cycloheximide (10 mg/ml). Every hour, cells
were harvested to prepare the total cell extracts. (A) p34cdc2/cy-
clin B complexes of total cell extracts prepared from nontreated
(– d –) or cycloheximide-treated cells (–s–) were immunoprecipi-
tated using the anti-cyclin B antibody and assayed for histone H1
kinase activities. (B) Proteins of total cell extracts prepared from
nontreated (2CHX) and CHX-treated (1CHX) cells were elec-
trophoresed in SDS-10% polyacrylamide gel and analyzed by im-
munoblotting using as a probe the antibodies against the proteins
indicated.Nishijima et al. Cdc25B, Starter of p34cdc2/Cyclin B Activation 1111
inhibitor cycloheximide. Since the accumulation of trun-
cated, abnormal proteins may enhance ubiquitin-depen-
dent proteolysis (Hershko, 1983), it is possible that
Cdc25B, which is stable in a normal growth condition, be-
comes unstable by blocking protein synthesis. To address
this question, Cdc25B was pulse labeled with [35S]me-
thionine and chased in the presence of an excess amount
of cold methionine in wild-type BHK21 cells that had been
arrested in S phase. As shown in Fig. 9 A, Cdc25B was rap-
idly lost even in the absence of cycloheximide. To further
confirm the instability of Cdc25B, human Cdc25B (a gift
of H. Okayama) was transfected into wild-type BHK21
cells, and the expressed human Cdc25B was pulse–chased
in randomly growing wild-type BHK21 cells. Exogenously
expressed human Cdc25B was rapidly lost with a half-life
of ,30 min, similar to the endogenous Cdc25B (Fig. 9, A
and B). In the same cultures of wild-type BHK21 cells ex-
pressing human Cdc25B, the endogenous hamster Cdc25B
was lost with the kinetics similar to that of human Cdc25B
(data not shown). Thus, Cdc25B was unstable in BHK21
cells, and the stability of Cdc25B was not changed by ar-
resting cells in S phase with hydroxyurea. Even in HeLa
cells, Cdc25B, but not Cdc25A and Cdc25C, was lost dur-
ing treatment with cycloheximide (Fig. 9 C). Taking these
results together, we concluded that Cdc25B was rapidly
turning over in mammalian cells.
All of p34cdc2 in the Extract Was Not Activated
by Cdc25B
To address the question whether the observed in vitro ac-
tivation of p34cdc2/cyclin B complex reflects a full activa-
tion of p34cdc2 within the extract, we added the E. coli-pro-
duced Cdc25C to the extract of BHK21 cells. By the
addition of E. coli-produced Cdc25C, the histone H1 ki-
nase activity was increased compared to the extract alone
(Fig. 10). This finding indicated that all of p34cdc2 in the ex-
tract was not activated by Cdc25B. Probably, in our reac-
tion condition, the activity of p34cdc2/cyclin B complexes
obtained by the in vitro incubation was not enough to
overcome the threshold for mitotic entrance, which is sup-
posed to be carried out by forming a positive feedback
mutual activation loop between Cdc25C and p34cdc2/cyclin
B complexes (Kumagai and Dunphy, 1992; Hoffmann et
al., 1993; Izumi and Maller, 1993). To address this issue,
we added an increasing amount of p34cdc2/cyclin B com-
plexes that had been activated by Cdc25B, to the extract of
S phase-arrested BHK21 cells. However, the high activa-
tion of the p34cdc2 that was obtained by the addition of E.
coli-produced Cdc25C, did not occur by the addition of ex-
tra p34cdc2/cyclin B complexes (data not shown). The similar
result has been reported by Lee et al. (1994a) using Xen-
opus egg extract.
Figure 6. Immunodepletion of Cdc25B blocks the in vitro activation of p34cdc2/cyclin B. Cytosolic extracts of wild-type BHK21 cells
treated (CHX-treated) or not treated (non-treated) with cycloheximide (10 mg/ml) were prepared as described in Fig. 4. From the extract
of nontreated cells, Cdc25B or Cdc25C was immunoprecipitated using the antibodies against Cdc25B and Cdc25C, respectively, and the
supernatants were used as the Cdc25B- or Cdc25C-immunodepleted extracts. (A) Proteins of the total and immunodepleted cytosolic
extracts were electrophoresed in SDS-10% polyacrylamide gel and analyzed by immunoblotting using the antibodies against indicated
proteins. Lanes 1 and 2, total cytosolic extract of cycloheximide-treated (CHX) and nontreated (non) cells. Lanes 3 and 4, Cdc25B- and
Cdc25C-depleted extract, respectively. (B) Total cytosolic extracts of cycloheximide-treated cells (CHX-treated) and nontreated (non-
treated) cells and the Cdc25B- or Cdc25C-depleted extracts of nontreated cells (designated as 2cdc25B and 2cdc25C, respectively)
were incubated at 308C. Before incubation (open column) and after incubation for 1 h (shaded column), the p34cdc2/cyclin B complexes
were immunoprecipitated using the anti-cyclin B antibody and assayed for histone H1 kinase activities. (C) From the cytosolic extract of
nontreated cells, cyclin B and then either Cdc25B or Cdc25C were immunodepleted using the antibodies against cyclin B, Cdc25B or
Cdc25C, respectively: cyclin B-depleted (2cyclin B), cyclin B- and Cdc25B-depleted (2cyclinB and 2cdc25B), and cyclin B- and
Cdc25C-depleted (2cyclin B and 2cdc25C) extracts. Total cytosolic extracts of cycloheximide-treated cells (CHX-treated) and the im-
munodepleted extracts from nontreated cells (non-treated) were incubated alone (open and shaded column) or after mixing with the to-
tal cytosolic extract of CHX-treated cells (filled column) at 308C. Before incubation (open column) and after incubation for 1 h (shaded
and filled column), the p34cdc2/cyclin B complexes were immunoprecipitated using the anti-cyclin B antibody and assayed for histone H1
kinase activities.The Journal of Cell Biology, Volume 138, 1997 1112
Over-Expression of Cdc25B Enhanced
Chromatin Condensation
To address whether Cdc25B is rate limiting for entry into
mitosis, increasing doses of Cdc25B cDNA were intro-
duced into wild-type BHK21 cells using lipofection. Trans-
fected cells were synchronized at G1 by isoleucine depriva-
tion and then at S phase with HU. After incubation for
15.5 h in the presence of HU, cells were stained with Hoechst
33342, and cells showing PCC were scanned with photomi-
croscope. There were no cells showing PCC (,0.1%). Next
we examined whether over-expressed Cdc25B can enhance
Figure 7. Cdc25B, but not Cdc25C, activates the p34cdc2/cyclin B
complexes of cycloheximide-treated cells. (A) Cdc25B proteins
were immunoprecipitated using the anti-Cdc25B antibody from
8, 24, and 48 ml of the cytosolic extracts derived from nontreated
(– d –) and, as a control, CHX-treated (–s–) wild-type BHK21
cells that had been arrested in S phase. The immunoprecipitated
Cdc25B prepared from the indicated volume of the cytosolic ex-
tract was then mixed with 8 ml of total cytosolic extract prepared
from cycloheximide-treated cells and as a control, with 8 ml of the
buffer (0.5 3 EB-1; nontreated: –h–; CHX-treated: -X-). A final
volume was adjusted to 30 ml. After incubation at 308C for 1 h,
p34cdc2/cyclin B was immunoprecipitated using the anti-cyclin B
antibody and assayed for histone H1 kinase activities. (B) A se-
ries of cultures of BHK21 cells was synchronized with HU in S
phase, and then half of the cultures was released from HU block
and arrested in M phase, as described in Materials and Methods.
The cytosolic extracts were prepared from the S phase-arrested
(–s–) and the M phase-arrested cells (–d–), respectively, and
then Cdc25C proteins were immunoprecipitated using the anti-
Cdc25C antibody from 15, 30, and 60 ml of the S and M phase ex-
tract. The immunoprecipitated Cdc25C prepared from the indi-
cated volume of the cytosolic extract was then mixed with 8 ml of
total cytosolic extract prepared from cycloheximide-treated cells.
A final volume was adjusted to 30 ml. After incubation at 308C for
1 h, p34cdc2/cyclin B was immunoprecipitated using the anti-cyclin
B antibody and assayed for histone H1 kinase activities.
Figure 8. Immunoprecipitated Cdc25B equally activated p34cdc2/
cyclin B complexes of cycloheximide-treated and nontreated
cells. From 8 ml of cytosolic extracts of nontreated (A) or cyclo-
heximide-treated (B) wild-type BHK21 cells, p34cdc2/cyclin B
complexes were immunoprecipitated using the anti-cyclin B anti-
body and then mixed with proteins immunoprecipitated with the
anti-Cdc25B antibodies from 8, 24, and 48 ml of cytosolic extracts
derived from cycloheximide-treated (–s–) and non-treated (–d–)
wild-type BHK21 cells. As a control, proteins immunoprecipi-
tated with the anti-Cdc25B antibodies were incubated by them-
selves in the buffer (0.5 3 EB-1; nontreated: –h–; CHX-treated:
-X-). A final volume was adjusted to 30 ml. After incubation at
308C for 1 h, p34cdc2/cyclin B was immunoprecipitated using the
anti-cyclin B antibody and assayed for histone H1 kinase activi-
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chromatin condensation induced by addition of caffeine.
HU-arrested cells were given 5 mM of caffeine along with
0.2  mg/ml of nocodazole and every hour, cells were
scanned for cells showing PCC by photomicroscope. As
shown in Fig. 11, the frequency of cells showing PCC was
increased in a dose-dependent manner of transfected
Cdc25B cDNA. When . 6 mg/35-mm dish of Cdc25B
cDNA was introduced into cells, cells rapidly died as pre-
viously reported (Makishima et al., 1997). Thus, the ques-
tion whether the amount of Cdc25B is rate limiting for en-
try into mitosis still remains to be answered. But our
present finding indicates that Cdc25B enhanced chromatin
condensation. Alternatively, it is possible that over-expressed
Cdc25B could not stimulate cells to enter mitosis due to
the tight cellular regulation of Cdc25B activity, since no
cells showing PCC appeared until 2 h after caffeine addi-
tion, even in the case of a higher dose of Cdc25B cDNA.
Discussion
Cdc25B Is a Short-Life Protein
The activation of p34cdc2/cyclin B occurs in the extract pre-
pared from S phase-arrested hamster BHK21 cells without
protein synthesis, but not in the extract of cells pretreated
with protein synthesis inhibitor cycloheximide, which in-
hibits the in vivo activation of p34cdc2/cyclin B as well. Taking
these results together, it can be deduced that S phase-
arrested hamster BHK21 cells possess all the molecules re-
quired for the observed activation of p34cdc2/cyclin B and
that either some molecules or protein modifications that
are required for the activation of p34cdc2/cyclin B were lost
by blocking protein synthesis. Since the p34cdc2/cyclin B
complexes of cycloheximide-treated cells can be directly
activated by immunoprecipitated Cdc25B, the modifica-
tion of p34cdc2/cyclin B may not be lost. It is, therefore, ra-
tional to consider that some molecule(s) essential for the
activation of p34cdc2/cyclin B is lost by blocking protein
synthesis.
Cyclins are most important proteins for the mitotic acti-
vation of p34cdc2/cyclin B, and their cellular contents
change depending on the cell cycle (Norbury and Nurse,
1992). In hamster BHK21 cells, cyclin B is present in S
phase-arrested cells as reported (Nishitani et al., 1991).
The amount of cyclin B, however, is not reduced by cyclo-
heximide treatment. The other protein that is essential for
the activation of p34cdc2/cyclin B is a family of dual-speci-
ficity phosphatase Cdc25 that perform dephosphorylation
of Thr-14 and Tyr-15 (Dunphy, 1994). Among the family
of Cdc25 phosphatases, we have found that Cdc25B, while
Cdc25A and Cdc25C are stable, is lost by blocking protein
synthesis. Indeed, the half-life of Cdc25B is ,30 min in
hamster BHK21, and also in HeLa cells. In this context,
Cdc25B is unique among the Cdc25 family. The finding
that human Cdc25B expressed in hamster wild-type
BHK21 has a short life similar to hamster Cdc25B suggests
that mammalian Cdc25B possesses a character of rapid
turn over. Consistent with the loss of Cdc25B by cyclohex-
imide treatment, the immunodepletion of Cdc25B from
the extract abrogates the in vitro activation of p34cdc2/cy-
clin B.
Cdc25B Functions as a Trigger for Mitosis
Previously we have found that Cdc25C is essential for
p34cdc2/cyclin B activation induced by the loss of RCC1
(Seki et al., 1992). However, Cdc25C is not required for
the observed in vitro activation of p34cdc2/cyclin B. Cdc25C
from mitotic cells activates p34cdc2/cyclin B within the ex-
Figure 9. Cdc25B is an unstable protein. (A) Endogenous hamster Cdc25B. Wild-type BHK21 cells were seeded at 1 3 106/100-mm
dish, synchronized in S phase, incubated in Met-free medium containing HU, labeled with [35S]l-methionine, and chased as described in
Materials and Methods. At the indicated times (min), cells were lysed and Cdc25B was immunoprecipitated and analyzed by autora-
diography. Human Cdc25B expressed in hamster BHK21 cells. Wild-type BHK21 cells were seeded at 2 3 106/100-mm dish. After 18 h
of incubation at 33.58C, cells were transfected with plasmid pcD2-human Cdc25B (16 mg/100-mm dish) using lipofection. After incuba-
tion in a normal medium for an additional 48 h at 33.58C, transfected cells were incubated in Met-free medium, labeled with [35S]l-methio-
nine, and chased as described in Materials and Methods. At the indicated times (min), cells were lysed and Cdc25B was immunoprecip-
itated and analyzed by autoradiography. (B) Half-life of Cdc25B. The radioactivity of immunoprecipitated, labeled endogenous
hamster (–s–) and expressed human (–d–) Cdc25B was counted by an analyzer (BAS2000; Bio Image, Ann Arbor, MI). The vertical
value indicates the relative count of radioactivity (Ct/C0). (C) Cultures of HeLa cells synchronized in S phase as described in Materials
and Methods were incubated for 1 h in the presence (CHX) or absence (non) of cycloheximide (10 mg/ml) and then lysed. Total proteins
of the extracts were electrophoresed in SDS-10% polyacrylamide gel and analyzed by immunoblotting using the antibodies against
Cdc25A, Cdc25B, and Cdc25C.The Journal of Cell Biology, Volume 138, 1997 1114
tract of cycloheximide-treated cells, but Cdc25C of S
phase-arrested cells does not. This finding is consistent
with the previous finding that during G2/M transition,
Cdc25C is phosphorylated and thereby activated, parallel
with the activation of p34cdc2/cyclin B (Kumagai and Dun-
phy, 1992; Izumi and Maller, 1993; Hoffmann et al., 1993).
In fact, the molecular mass of Cdc25C in S phase-arrested
cells is not high like in mitotic cells. It has been reported
that Cdc25C has a low activity of tyrosine phosphatase
even in the interphase (Kumagai and Dunphy, 1992; Izumi
and Maller, 1993; Hoffmann et al., 1994). We think that
the discrepancy between our results and the previous ones
may be due to the difference in materials. We stringently
synchronized BHK21 cells into S phase by using the step-
wise method; that is, first, cells were arrested in G0/G1 by
isoleucine deprivation and then in S phase with HU.
In tsBN2 cells arrested in S phase, the activation of
p34cdc2/cyclin B can be induced at 408C, the nonpermissive
temperature, and in parallel with the activation of p34cdc2/
cyclin B, p34cdc2 is dephosphorylated and Cdc25C is phos-
phorylated (Nishitani et al., 1991; Seki et al., 1992; current
study), as found in Xenopus extract (Kumagai and Dun-
phy, 1992; Izumi and Maller, 1993; Hoffmann et al., 1993).
Based on these observations, we assume that the prema-
ture activation of p34cdc2/cyclin B induced by tsBN2 muta-
tion mimics a normal entrance of mitosis. In this context,
we notice that loss of Cdc25B is coincident with loss of
p34cdc2/cyclin B activation, both in vivo and in vitro. Inter-
estingly, the content of Cdc25B was reduced in parallel
with the activation of p34cdc2/cyclin B and the molecular
shift of Cdc25C. These findings may suggest that Cdc25B
initially activates the p34cdc2/cyclin B complexes, which, in
turn, phosphorylate Cdc25C, forming a positive feedback,
mutual activation loop between Cdc25C and p34cdc2/cyclin
B. Consistent with the notion that Cdc25B functions as a
trigger for the initiation of mitosis, the in vitro activation
of p34cdc2/cyclin B carried out by Cdc25B is lower com-
pared to the activation of p34cdc2/cyclin B that is carried
out by constitutively active E. coli-produced Cdc25C.
To prove that Cdc25B is a “starter” for the mitotic acti-
vation of p34cdc2, it will be essential to show that the anti-
body to Cdc25B that neutralizes the enzyme activity of
Cdc25B blocks the initiation of mitosis in mammalian
cells.
Cellular Regulation of Cdc25B Function
While Cdc25C is activated by phosphorylation (Izumi et
al., 1992; Kumagai and Dunphy, 1992, 1996), it is not yet
clear how Cdc25B is activated. The finding that Cdc25B
immunoprecipitated before the in vitro incubation acti-
vates the p34cdc2/cyclin B complexes that were isolated
from cycloheximide-treated cells indicates that the Cdc25B
of S phase-arrested BHK21 cells is active. If Cdc25B is al-
ready active in cells, there must be some regulatory system
to prevent the p34cdc2/cyclin B from the premature activa-
tion. In this context, the in vitro spontaneous activation of
p34cdc2/cyclin B in the cell extract suggests that the cell dis-
ruption that may mimic loss of the cellular compartment
causes an activation of p34cdc2/cyclin B. In the interphase,
therefore, we assume that the compartment mechanism
that restrains an interaction between an enzyme and its
substrate may play a role in the regulation of p34cdc2/cyclin
B activation. In human HeLa cells, cyclin B1 is anchored
in the cytoplasm during the interphase and enters the nu-
cleus at the beginning of mitosis (Pines and Hunter, 1991,
1994). Recently, Nim1, which phosphorylates and thereby
inhibits Wee1, is found to be localized in the cytoplasm,
Figure 10. Activation of p34cdc2 within the cytosolic extract of cy-
cloheximide-treated and nontreated cells by E. coli-produced
hamster Cdc25B. Cultures of BHK21 cells were synchronized
with HU as described in Materials and Methods, and half of the
cultures were treated with cycloheximide (10 mg/ml) for 1 h be-
fore cell disruption. 8 ml of cytosolic extracts of nontreated (–d–,
–j–) or cycloheximide-treated (–s–, –h–) cultures were incu-
bated at 308C for indicated time (min), in the presence (–j–, –h–)
or absence (–d–, –s–) of E. coli-produced hamster Cdc25C (final
concentration 100 mg/ml). A final volume was adjusted to 30 ml.
After incubation, p34cdc2/cyclin B was immunoprecipitated using
the anti-cyclin B antibody and assayed for histone H1 kinase ac-
tivities.
Figure 11. Over-expression of Cdc25B enhances chromatin con-
densation induced by caffeine. Wild-type BHK21 cells were
seeded at 2 3 105/35-mm dish. After 23 h of incubation at 33.58C,
cells were transfected with the indicated doses of pcD2-Cdc25B
DNA. After transfection, cells were synchronized at S phase by
isoleucine deprivation and HU as described in Materials and
Methods. After S phase arrest, cells were given caffeine (final
concentration 5 mM) and nocodazole (final concentration 0.2 mg/
ml) in the presence of HU and then incubated at 37.58C. Every 2 h
cells were fixed with cold methanol and stained with Hoechst
33342. More than 1,000 cells were scored for PCC. The frequency
of cells showing PCC is shown on the vertical axis. Amount of
transfected DNA: –s–, 0 mg/dish ; –d–, 1 mg/dish; –h–, 2 mg/dish;
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whereas Wee1 is localized in the nucleus (Parker and Pi-
wnica-Worms, 1992; McGowan and Russell, 1993; Heald
et al., 1993; Wu et al., 1996). In both mammalian and yeast,
thus, the cellular compartment of proteins seems to play a
role in regulating the initiation of mitosis. In this regard,
we notice that loss of RCC1, which performs GDP/GTP
exchange of Ran GTPase (Bischoff and Ponstingl, 1991),
induces the activation of p34cdc2/cyclin B (Nishitani et al.,
1991). The Ran GTPase is essential for nucleus/cytosol ex-
change of macromolecules (Melchior et al., 1993; Moore
and Blobel, 1993) and for nuclear processing of mRNA
(Sazer, 1996; Seki et al., 1996). Loss of RCC1 may accumu-
late the GDP-bound form of Ran GTPase, thereby, dis-
turbing the Ran GTPase cycle. We are tempted to specu-
late, therefore, that the cellular compartment required for
the cell cycle progression is regulated by the Ran GTPase.
Unstable Triggers and Stable Inhibitors for the 
Initiation of Mitosis
Although we could not exclude the possibility that the
other unstable proteins like Cdc25B are also required for
the initiation of mitosis, our findings indicate that the acti-
vator(s) is rapidly turning over, but the inhibitor(s) is sta-
ble. In S phase-arrested BHK21 cells, the activator(s) and
the inhibitor(s) for p34cdc2/cyclin B seem to be balanced,
and thereby, cells do not enter mitosis. The instability of
the p34cdc2/cyclin B activator(s) may reflect an adaptation
of cells to stresses, including the inhibition of protein syn-
thesis. In such circumstances, it is better for cells to remain
in a less active state of p34cdc2/cyclin B, or otherwise cells
will suffer further damage from proceeding through the
cell cycle. In this context, it seems to be reasonable that
the ‘starter’ for the mitotic entrance is labile.
By loss of the activator(s), the presence of p34cdc2/cyclin
B inhibitor(s) became obvious. It is also possible that the
inhibitor(s) was activated by cycloheximide treatment. In
mammalian cells, the inhibitory kinases for p34cdc2/cyclin
B like Wee1 and Myt1 (Parker and Piwnica-Worms, 1992;
Mueller et al., 1995a,b), the phosphatase INH/PP2A (Cyert
and Kirschner, 1988; Lee et al., 1991, 1994a) and the
stoichiometric inhibitors (Kumagai and Dunphy, 1995;
Lee and Kirschner, 1996) have been reported to prevent
the activation of p34cdc2/cyclin B in the interphase. The
finding that the addition of p34cdc2/cyclin B complexes pre-
activated by Cdc25B could not induce a full activation of
p34cdc2/cyclin B in the extract, suggests that our extracts
contain the inhibitory kinase of p34cdc2/cyclin B or the
phosphatase INH/PP2A.
In summary, our results indicate that Cdc25B functions
as a trigger for mitosis. Our finding that Cdc25B is an un-
stable trigger for the entrance of mitosis will provide a new
aspect regarding the check point control. In S. pombe, the
level of Cdc25 is regulated by ubiquitin ligase Pub1 (Nef-
sky and Beach, 1996). Probably it is also true in mamma-
lian cells. The stabilization of Cdc25B, therefore, may dis-
turb the cell cycle control at the G2/M transition.
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